Galapagos’ (GLPG) “Sell” Rating Reaffirmed at Deutsche Bank Aktiengesellschaft

Galapagos (NASDAQ:GLPG)‘s stock had its “sell” rating reaffirmed by investment analysts at Deutsche Bank Aktiengesellschaft in a research note issued on Tuesday, MarketBeat.com reports.

Separately, Wall Street Zen raised Galapagos from a “sell” rating to a “hold” rating in a research report on Saturday, July 26th. Five investment analysts have rated the stock with a sell rating and four have given a hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus price target of $25.33.

Galapagos Price Performance

Galapagos stock traded down $0.18 during mid-day trading on Tuesday, hitting $32.82. The stock had a trading volume of 329,270 shares, compared to its average volume of 331,783. The stock has a 50-day simple moving average of $29.72 and a two-hundred day simple moving average of $26.93. Galapagos has a 12 month low of $22.36 and a 12 month high of $33.86.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Wealthquest Corp bought a new position in Galapagos in the first quarter valued at approximately $74,000. BNP Paribas Financial Markets boosted its stake in shares of Galapagos by 45.9% during the 4th quarter. BNP Paribas Financial Markets now owns 8,972 shares of the biotechnology company’s stock worth $247,000 after acquiring an additional 2,824 shares during the period. GAMMA Investing LLC boosted its stake in shares of Galapagos by 354.5% during the 1st quarter. GAMMA Investing LLC now owns 10,148 shares of the biotechnology company’s stock worth $255,000 after acquiring an additional 7,915 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in shares of Galapagos during the 2nd quarter worth approximately $261,000. Finally, Wealthedge Investment Advisors LLC bought a new position in shares of Galapagos during the 4th quarter worth approximately $311,000. 32.46% of the stock is currently owned by institutional investors.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.